Immutep's Pioneering Phase III Trial for Lung Cancer
Immutep Limited (ASX: IMM; NASDAQ: IMMP) is embarking on a pivotal journey in the field of oncology with the announcement of its TACTI-004 Phase III clinical trial, aimed at treating first-line metastatic non-small cell lung cancer (1L NSCLC). This initiative represents a crucial milestone in the company’s trajectory as a clinical-stage biotechnology firm, focused on innovative immunotherapies.
The Significance of TACTI-004 Trial
With the approval from the Australian Therapeutic Goods Administration, Immutep is set to initiate this essential Phase III trial, highlighting a transformative moment for the company. CEO Marc Voigt expressed optimism about the potential of eftilagimod alfa, a LAG-3 immunotherapy, stating that he anticipates it will significantly enhance patients’ lives battling metastatic NSCLC. The trial aims to set a new standard of care, combining cutting-edge therapies to improve treatment outcomes.
Details About the Trial
The TACTI-004 trial will evaluate the effectiveness of eftilagimod alfa in combination with the well-known anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), along with chemotherapy. The study will involve approximately 750 patients diagnosed with 1L NSCLC, and it is designed as a double-blind, randomized, controlled trial. This substantial trial is set to take place across more than 150 clinical sites in over 25 countries, providing a robust global perspective on the findings.
Anticipating Participation and Outcomes
As Immutep prepares to commence enrollment, the first patient is expected to be welcomed into the study in the first quarter of 2025. This trial aims not only to analyze primary endpoints such as progression-free survival and overall survival but also to shed light on the role of LAG-3 in cancer treatment.
Collaboration and Regulatory Approvals
Immutep has effectively secured necessary approvals from multiple regulatory bodies, ensuring a smooth start to the TACTI-004 trial. This collaboration with MSD, the parent company of KEYTRUDA, underscores a significant partnership in advancing cancer therapies globally. With expectations of further approvals from countries beyond Australia and the UK, the company is laying down the groundwork for a comprehensive and inclusive trial.
About Immutep: Innovation in Immunotherapy
Established as a leader in the realm of LAG-3 immunotherapy, Immutep is instrumental in developing treatments that target the immune response in various diseases, including cancer. Their innovative approach towards therapeutics focused on LAG-3 is pivotal in creating options that stimulate or regulate the immune system effectively. Through their diverse portfolio, Immutep is committed to addressing unmet medical needs while also creating value for their shareholders.
Community and Shareholder Engagement
Immutep’s dedication extends beyond clinical trials; they strive to maintain transparent communication with investors and the community at large. The company emphasizes the importance of engaging with stakeholders to garner support for their clinical endeavors and ensure shared success.
Frequently Asked Questions
What is the main focus of the TACTI-004 trial?
The TACTI-004 trial aims to evaluate the efficacy of eftilagimod alfa in combination therapies for patients with metastatic non-small cell lung cancer.
When is the trial expected to enroll its first patient?
The trial is anticipated to enroll its first patient in the first quarter of 2025.
How many countries are involved in the TACTI-004 trial?
Over 25 countries will participate in the TACTI-004 trial, ensuring a diverse patient population.
What are the primary endpoints of the trial?
The primary endpoints of the trial include progression-free survival and overall survival.
Who can be contacted for further information about Immutep?
Catherine Strong from Sodali & Co. or Chris Basta from Immutep's Investor Relations can be contacted for further inquiries.
